Lipocine (STU:2VT0) ROE % Adjusted to Book Value: -53.11% (As of Mar. 2026)

Lipocine STU:2VT0 50 ROE % Adjusted to Book Value is -53.11% as of Mar. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 50/100 and a GF Value™ of €2.90. The stock has 4 warning signs investors should review.

Lipocine's ROE % for the quarter that ended in Mar. 2026 was -79.13%. Lipocine's PB Ratio for the quarter that ended in Mar. 2026 was 1.49. Lipocine's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -53.11%.

Lipocine ROE % Adjusted to Book Value Related Terms

Lipocine ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Lipocine's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine ROE % Adjusted to Book Value Chart

Lipocine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-1.11

-28.60

-51.18

0.04

-25.88

Lipocine Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-30.67	-32.82	-45.62	-33.84	-53.11

STU:2VT0 vs NCEL, PTN, ALLR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Lipocine's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipocine ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lipocine's ROE % Adjusted to Book Value falls into.

Save Embed

50GF Score

Lipocine Inc STU:2VT0

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lipocine ROE % Adjusted to Book Value Calculation

Lipocine's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-50.73%	/	1.96
	=	-25.88%

Lipocine's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-79.13%	/	1.49
	=	-53.11%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of -53.11% mean?

Lipocine (STU:2VT0) has a ROE % Adjusted to Book Value of -53.11% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lipocine and its competitors.

Is Lipocine's ROE % Adjusted to Book Value too high?

Lipocine's current ROE % Adjusted to Book Value is -53.11%. Overall, Lipocine has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.

How does Lipocine's ROE % Adjusted to Book Value compare to NCEL and PTN?

Lipocine's ROE % Adjusted to Book Value of -53.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lipocine and its competitors. Lipocine's current ROE % Adjusted to Book Value is -53.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lipocine stock overvalued right now?

Lipocine (STU:2VT0) has a current ROE % Adjusted to Book Value of -53.11%. The stock's GF Value™ is €2.90, compared to a current price of €3.94 — trading 36% above its estimated fair value. The current ROE % Adjusted to Book Value is -53.11%. Lipocine's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current ROE % Adjusted to Book Value is -53.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 36% above its estimated GF Value™ of €2.90.

Key valuation signals for STU:2VT0:

ROE % Adjusted to Book Value: -53.11%
GF Value™: €2.90 vs. price of €3.94 (36% above fair value)
GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lipocine Business Description

Industry Healthcare Biotechnology

Comparable Companies NCEL PTN ALLR CLRB OTLC CVM VYNE AEON PLUR MRKR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges LPCN:USA

Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108

Website https://www.lipocine.com

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

50GF Score

Get the complete analysis for STU:2VT0

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94

Price

€2.90

GF Value

View STU:2VT0 Analysis

See ROE % Adjusted to Book Value data for all stocks →